Psomagen Inc.

Psomagen Inc., a foreign-owned, for-profit subsidiary of South Korea-based Macrogen, Inc. based in Rockville, Maryland, provides genomic sequencing, proteomics analysis, and multi-omics data integration services to federal research agencies as a prime contractor, competing predominantly under full-and-open procurements with no recurring set-aside designation. Psomagen operates CLIA-certified and CAP-accredited laboratory facilities and delivers a portfolio spanning whole genome sequencing, RNA sequencing, single-cell genomics, Olink proteomics assays, epigenome sequencing, and bioinformatics analysis in support of precision medicine, neurodegenerative disease research, cancer genomics, infectious disease investigations, and agricultural genetics initiatives.

The customer concentration is extreme and anchored by a single vehicle: the National Heart, Lung and Blood Institute (NHLBI) dominates the footprint with 26 awards carrying $501.6 million in combined potential value—95% of Psomagen's total federal potential across 226 awards. The $500 million single-award Indefinite Delivery Contract for the Trans-Omics for Precision Medicine (TOPMed) initiative, awarded September 12, 2023 and running through September 11, 2033, establishes and operates the Centralized Omics Resource to provide multi-omics data analysis, integration, and informatics capabilities for cardiovascular, lung, blood, and sleep disorders research. The National Institute on Aging ranks second with 20 awards ($14.6 million combined potential value) supporting neurodegenerative disease research through whole genome sequencing, RNA sequencing, single-cell multiome sequencing, and epigenome sequencing services. The National Institute of Allergy and Infectious Diseases and subordinate DEA offices rank third and fourth (23 awards combined, $570 thousand combined potential value) for COVID-19 research, infectious disease sequencing, and library preparation work. The Department of Agriculture Agricultural Research Service and related field offices place 11 awards ($140 thousand combined potential value) for wheat sequencing, fish RNA-seq, and agricultural genetics support. Forty distinct federal agencies have awarded Psomagen work, but the top five account for 99% of the combined potential-value total. The vendor also holds a single-award USDA Indefinite Delivery Contract (12639524D0015) valued at $80,000 for Sanger sequencing services supporting Plant Protection and Quarantine pest identification.

Recent prime contract examples illustrate the capability breadth. Psomagen received a $7.5 million National Institute on Aging purchase order (awarded August 20, 2024) for whole genome sequencing on 500 neurodegenerative disease samples under a Total Small Business set-aside, with completion by September 24, 2025. A $532.5 million National Institute on Aging award (January 6, 2025) for long-read sequencing supporting the Global Parkinson's Genetics Program required 500 human DNA samples at 25X coverage. A $3.85 million National Institute on Aging purchase order (July 25, 2023) supported neurodegenerative disease research through whole genome sequencing under a Total Small Business set-aside. A $229.1 million NHLBI purchase order (February 10, 2025) investigated transthyretin variants and sickle cell disease severity using Olink proteomics. The Defense Health Agency issued a $30.8 thousand purchase order (August 15, 2026) for Olink Target 96 certified assay services analyzing de-identified plasma samples for metabolism, inflammation, and immune response biomarkers. The National Cancer Institute awarded a $25 thousand purchase order (September 21, 2026) on sole-source authority for 10X Chromium GEM-X single-cell RNA sequencing library generation and expression analysis on frozen clinical xenograft biosamples, citing Psomagen's proprietary service ownership and integration with NCI's research data infrastructure as justification for direct negotiation.

Activity has been volatile: 17 awards in 2022, declining to 11 in 2023, then rising to 21 in 2024, 16 in 2025, and 7 awards in 2026 year-to-date. Only 6 awards (combined potential value $348 thousand) reach ultimate completion inside the next twenty-four months, posing minimal recompete exposure. The vendor competes predominantly on a full-and-open basis; although several recent contracts carry Total Small Business set-aside designation—notably a 2024 National Institute on Aging $7.5 million whole genome sequencing award and a 2025 NIA long-read sequencing award—Psomagen's core NHLBI TOPMed vehicle and the majority of its NIH work appear full-and-open.

Service Contract Inventory data covering federal service contracts above the $150,000 threshold shows SCI-reported invoiced revenue of $3.6 million across FY2022–FY2025 (FY2022: $533 thousand; FY2023: $609 thousand; FY2024: $2.5 million; FY2025: zero), with federal FTE delivery averaging 0.3 FTEs across the SCI-reportable prime portfolio. On federal services contracts captured in SCI, government-paid hourly rates median around $1,303/hr, with senior labor pricing through $1,824/hr and entry-level work around $626/hr. Across SCI-reportable prime contracts, subcontractors performed 0% of contractor hours; Psomagen builds and executes its own federal delivery teams with no material sub-engagement. The vendor subcontracts to KBR Wyle Services, LLC on one recent award (August 27, 2026) for next-generation sequencing, targeted proteomics, and sample analysis services under an HHPC2 vehicle, indicating occasional prime-to-sub teaming on larger programs. As a subsidiary of Macrogen, Inc., Psomagen leverages parent-company genomic capabilities and infrastructure but operates as an independent federal prime contractor.